ORPHA:97566
Non-amyloid fibrillary glomerulopathy
Also known as: Congo red-negative amyloidosis-like glomerulopathy · Non-amyloid fibrillary glomerulonephritis
Publications
665
88.6th percentile
Trials
4
Interventional, condition-specific
Researchers
1,071
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Non-amyloid fibrillary glomerulopathy (non-amyloid FGP) is a rare cause of glomerulonephritis (GN) characterized by glomerular accumulation of non-amyloid fibrils in the mesangium and the glomerular (and rarely tubular) basement membrane, that mainly presents with renal insufficiency, micro-hematuria and nephrotic range proteinuria. Non-amyloid FGP and immunotactoid glomerulopathy (ITG) are often grouped together as pathogenetically related diseases.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019990
- UMLS:C4273674
Additional Mondo synonyms (2)
Fibrillary Glomerulonephritis · non-amyloid fibrillary glomerulonephritis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
665 matched papers (419 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
4 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
665
665 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
665 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
419 in the last 10 years · medium confidence · 88.6th percentile (publications denominator)
Phrase hits: 665 · MeSH hits: 0
Who's working on it?
1,071
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Nasr SH12 papers · 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Papers in Europe PMC - 02Alexander MP9 papers · 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Alexander.Mariam@mayo.edu.
Papers in Europe PMC - 03Shimizu A9 papers · 2026
Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.
Papers in Europe PMC - 04Andeen NK7 papers · 2022
Department of Pathology, Oregon Health & Science University, Portland, Oregon, USA. Electronic address: andeen@ohsu.edu.
Papers in Europe PMC - 05Leung N7 papers · 2023
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Papers in Europe PMC - 06Batal I6 papers · 2025
Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
Papers in Europe PMC - 07Fervenza FC6 papers · 2026
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Papers in Europe PMC - 08Sethi S5 papers · 2026
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Papers in Europe PMC - 09Barreca A4 papers · 2026
Division of Pathology, Città della Salute e della Scienza Hospital, Turin, Italy.
Papers in Europe PMC - 10Li X4 papers · 2026
Department of Nephrology, Gansu Provincial Hospital, Lanzhou, 730000, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
4
interventional trials for this specific condition
4 interventional trials matched this specific condition name; 1 currently recruiting in our sample.
Data as of 27 July 2026
4 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 86.7th percentile).
medium confidence · 86.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
4 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06295770·RECRUITING·Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
Conditions: Fibrillary Glomerulonephritis·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06065852·RECRUITING·National Registry of Rare Kidney Diseases
Conditions: Adenine Phosphoribosyltransferase Deficiency · AH Amyloidosis · AHL Amyloidosis · AL Amyloidosis·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Non-amyloid fibrillary glomerulopathy" OR "Congo red-negative amyloidosis-like glomerulopathy" OR "Non-amyloid fibrillary glomerulonephritis" OR "Fibrillary Glomerulonephritis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Non-amyloid fibrillary glomerulopathy" OR "Congo red-negative amyloidosis-like glomerulopathy" OR "Non-amyloid fibrillary glomerulonephritis" OR "Fibrillary Glomerulonephritis"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 4 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- "Fibrillary Glomerulonephritis" also appears on ORPHA:97567
Ingested 2026-07-27T05:17:17.062Z